Table 2.
Herbal compounds | In vitro or animal studies | Human studies | Effects on RGCs | Effects on IOP |
---|---|---|---|---|
Ginkgo biloba | 2 | 2 | Possible reduction of the damage induced by oxidant agents both in animal models and in NTG patients [30–33] No data on POAG patients |
Not demonstrated |
| ||||
Scutellaria baicalensis Georgi | 4 | — | Strong capacity to protect RGCs from oxidative stress in animal and in vitro models [52–54, 56] No data on human models |
Not demonstrated |
| ||||
Crocus sativus L. | 1 | 2 | Neuroprotective effects derived from antioxidant and anti-inflammatory effects both in animal models and in POAG patients [65] No data on NTG patients |
Conflicting results from human studies on POAG patients [67, 68] No data on NTG patients |
| ||||
Coleus forskohlii | 3 | 4 | Not demonstrated | Conflicting results from studies on animal models, healthy people, and POAG patients [79–85] No data on NTG patients |
| ||||
Vaccinium myrtillus | 1 | 3 | Neuroprotective effects through retinal microcirculation improvement both in animal and human models [93] | Slight IOP reduction if administered orally in patients with ocular hypertension [94–96] No data on POAG and NTG patients |
| ||||
Ribes nigrum L. | — | 3 | Neuroprotective effects through ocular blood flow improvement in POAG patients [97, 98] No data on NTG patients |
IOP decrease both in healthy people and POAG patients [99] No data on POAG patients |
| ||||
Erigeron breviscapus | — | 1 | Stimulating effects in POAG patients with IOP in a controlled range [102] No data on NTG patients |
Not demonstrated |
| ||||
Salvia miltiorrhiza | 1 | 1 | Neuroprotective effects on animal model and POAG patients [104, 105] No data on NTG patients |
Not demonstrated |